1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. MARK

MARK

Microtubule affinity regulating kinase

Microtubule affinity-regulating kinases belong to the calcium/calmodulin-dependent protein kinase superfamily. MARKs and their homologs are functionally diverse protein kinases, possessing functional roles in cell polarity, microtubule stability, cell cycle control and intracellular signaling. Phosphorylation of the catalytic kinase domain (KD) by upstream kinases like MARKK (MARK kinase) can lead to activation of MARK. Activated MARK can phosphorylate tau protein and other related MAP proteins such as MAP2 and MAP4, which have affinities for stabilizing microtubules, and also can phosphorylate other proteins involved in cell signaling and 14-3-3 (also known as Par 5, partitioning defective protein 5) binding.

MARK Related Products (10):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-120877
    MRT199665
    Inhibitor 99.74%
    MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.
    MRT199665
  • HY-139604
    PCC0208017
    Inhibitor 98.03%
    PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability.
    PCC0208017
  • HY-114317
    MARK4 inhibitor 1
    Inhibitor 98.29%
    MARK4 inhibitor 1 is a potent and selective microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis.
    MARK4 inhibitor 1
  • HY-112266
    MARK-IN-4
    Inhibitor 98.99%
    MARK-IN-4 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 1 nM. Inhibition of microtubule affinity regulating kinase (MARK) represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease.
    MARK-IN-4
  • HY-101934
    MARK-IN-2
    Inhibitor 99.19%
    MARK-IN-2 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC50 of 5 nM.
    MARK-IN-2
  • HY-159113
    PCC0105003
    Inhibitor
    PCC0105003 is a potent MARK inhibitor. PCC0105003 can be used in the study of neuropathic pain.
    PCC0105003
  • HY-120877A
    (R)-MRT199665
    Inhibitor
    (R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.
    (R)-MRT199665
  • HY-154988
    MARK4 inhibitor 4
    99.23%
    MARK4 inhibitor 4 is a MARK4 inhibitor with an IC50 of 1.49 μM. MARK4 inhibitor 4 can be used in cancer and tau lesion-related research.
    MARK4 inhibitor 4
  • HY-154986
    MARK4 inhibitor 2
    Inhibitor 99.47%
    MARK4 inhibitor 2 is an inhibitor of microtubule affinity-regulating kinase 4 (MARK4) with an Km of 6.3×10 7 and an IC50 of 0.82 μM. MARK4 inhibitor 2 inhibits the growth of human cells and can be used for cancer research.
    MARK4 inhibitor 2
  • HY-154987
    MARK4 inhibitor 3
    MAPK4 inhibitor 3 (compound 23b) is an inhibitor of MAPK4 with an IC50 value of 1.01 μM. MAPK4 inhibitor 3 inhibits cancer cells growth. MAPK4 inhibitor 3 can be used for research on cancer and tauopathies.
    MARK4 inhibitor 3